Tag: Daiichi Sankyo
Gilles Gallant, BPharm, PhD, FOPQ, Receives the 2022 George R. Pettit...
Gilles Gallant, BPharm, Ph.D., FOPQ, Chief Development Officer, at Mythic Therapeutics has received the George R. Pettit Individual Input to the Field Award for 2022. The award was presented at the 13th World ADC Conference, held in San Diego, CA, during the 9th World ADC Awards Ceremony held on Thursday, September 8, 2022.
US FDA Approves Trastuzumab Deruxtecan for the treatment of HER2-Mutant NSCLC
The United States Food and Drug Administration (FDA) has approved trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with...
Trastuzumab deruxtecan Doubles Progression-Free Survival in Metastatic Breast Cancer with Low...
The use of trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival (PFS) compared to standard-of-care treatment with...
The Rise of HER2-targeting ADCs and the Journey from Breakthrough Therapy...
Antibody-drug conjugates (ADCs) as precision targeted cancer therapies have started to deliver on their early promise as an innovative novel drug modality as demonstrated...
First patient Dosed with Trastuzumab Deruxtecan in DESTINY-Breast09 Head-to-Head HER2+ mBC...
A first patient was dosed in DESTINY-Breast09 (NCT04784715), a global head-to-head Phase 3 clinical trial evaluating the safety and efficacy of trastuzumab deruxtecan (Enhertu®;...
Patritumab Deruxtecan Shows Tumor Response Across Multiple Resistance Mechanisms in Patients...
New data presented at this year’s annual meeting of the American Society of Clinical Oncology, held online June 4 - 8, 2021, confirms promising...
Daiichi Sankyo Reaffirms Long-term Goals with Increased Investment in ADCs
With the launch of fam-trastuzumab-deruxtecan-nxki (Enhertu®), Daiichi Sankyo's first antibody-drug conjugates, coupled with a strong pipeline of innovative ADC, the company has established a...
José Baselga, a Leading Cancer Researcher, Dies at 61
José Baselga, MD, Ph.D., an internationally renowned expert in the development of molecular targeted agents, the R&D chief at AstraZeneca, who had earlier been...
Daiichi Sankyo: Realigning for Agility
Daiichi Sankyo first approached me in 2015 with a potential opportunity in global oncology development, and I listened carefully as they explained how they...
First Patients Dosed in Phase II Study of Patritumab Deruxtecan in...
A first patient was doses in a phase II clinical trial designed to evaluate patritumab deruxtecan (previously known as U3-1402), a HER3 directed DXd...
